Yingke Capital

Yingke Capital is a principal investment firm based in Fuzhou, China, founded in 2010 by Mingfei Qian. The firm specializes in private equity investments across various sectors, including 5G internet of things, biomedical, environmental services, new energy, consumer upgrades, and smart manufacturing. Yingke Capital primarily focuses on pre-IPO investments and targets companies with strong technology research and development capabilities and production capacity. Additionally, it manages the Yingke Capital Science and Technology Innovation Industry Fund, which concentrates on growth investments in information technology, pharmaceuticals, and biotechnology sectors. Through its investment strategies, Yingke Capital aims to support the development of unlisted companies at various stages, from angel investments to pre-IPO funding, while also offering asset management and investment banking services.

Yulei Chen

Chief Investment Officer and President

Lai, Manying

President

Xu, Ling

President

Wu, Shuqing

President of Financial Division

Xiaochen Zhou

Vice President

51 past transactions

Fourier

Series C in 2022
Fourier is a semiconductor company. They design a complex structure digital-analog hybrid chip. They provide products that include car audio amplifiers, mid and high-power audio amplifiers, smart audio amplifiers, SPC audio amplifiers, haptic drivers, power management, and more.

CanSemi

Private Equity Round in 2022
CanSemi is a chip manufacturing plant that manufactures microprocessors, power management chips, analog chips, and power discrete devices.

Changrong Electric

Private Equity Round in 2022
Changrong Electric is a research and development and manufacture of motor sensor protectors, current sensors, motor controllers, drivers.

Chinagene Tech

Series A in 2022
Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical genetic diagnosis services for hereditary ophthalmology patients.

Gene Vector

Seed Round in 2022
Chengdu Genevector Biotechnology Co., Ltd. (Genevector, Genevector) is a biotechnology company engaged in the research and development of new drugs for adeno-associated virus (AAV) gene therapy. The company is committed to the development of new AAV gene therapy drugs for ophthalmic diseases, neuromuscular diseases, genetic and metabolic diseases, etc.

Cloudbreak Therapeutics

Series C in 2022
Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Cloudbreak Therapeutics operates a capital efficient business model based upon VIC + 505b(2). We repurpose approved systemic drugs for ocular delivery to treat eye diseases and quickly advance drug candidates to complete proof-of-concept (POC) Phase II clinical trials and to out-license global rights for Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC and clinical development to efficiently maximize capital for drug development.
Chengman Power is a one-stop lithium battery energy service solution provider, focusing on exploring more application scenarios of lithium battery energy and establishing an innovative form of lithium battery energy consumption. It has the operating capabilities covering the full life cycle of lithium batteries, including charging, overhauling, maintenance, leasing, replacement, secondary utilization, echelon, iteration, etc., providing customers with professional battery operation management to achieve safe, efficient, and recycling energy. . Service areas: shared motorcycles, battery swap companies, express riders, C-end consumers, tricycles, automobiles, and other battery flow scenarios.

Aoxion Technology

Series A in 2021
Aoxion Technology is a high-tech enterprise with core handwriting AI recognition technology, committed to providing full-scene digital solutions for judicial evidence for government, enterprise and public institutions. Based on the new generation of information technology such as big data, artificial intelligence, cloud computing, and blockchain, the company provides customers with a four-in-one full-stack signing service of "digital certificate and smart signing", which fully empowers paper documents electronically and electronically. Documents are digitized and data archives are evidenced to solve the last piece of paper in the digital society.

UnionTech 3D

Series D in 2021
UnionTech 3D is active in the field of stereolithography 3D printing. This additive manufacturing technology makes it possible, to produce highly accurate and detailed polymer parts.

Greatpower Technology

Series C in 2021
Greatpower Technology is a plant for nickel sulphate, a major ingredient for lithium-ion batteries used in electric vehicles.

Tage Zhixing

Series B in 2021
Beijing Tage Zhixing Technology Co., Ltd. is a high-tech enterprise focusing on mining vehicle unmanned driving technology research, product development, and overall engineering solution design and implementation of unmanned mines. Tage Zhixing has launched a car-ground-cloud collaborative smart mine unmanned transportation system, which realizes cloud intelligent dispatching management, 4G.

Abogen Biosciences

Series C in 2021
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Beijing Health Guard Biotechnology

Private Equity Round in 2021
Beijing Health Guard Biotechnology is a research and development company that develops recombinant protein drugs for the biotech industry. The company also specializes in the research and development of novel biopharmaceuticals featuring a structure-guided design approach. Beijing Health Guard Biotechnology was founded in 2008 and is based in Beijing, China.

Berry Oncology

Series B in 2021
Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer. The company's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market.

JOINN Biologics

Series B in 2021
JOINN Biologics is a California Bay Area-based company that is committed to the advancement of biotech and biopharmaceutics through our premier contract manufacturing and development services for biologics and advanced therapies. A vital part of the JOINN Family's successful 20+ year track record of supporting drug discovery and development, we provide a complete range of CDMO services, from early development to clinical manufacturing, for our clients and partners on a global scale. Core Capabilities • Molecular/developability assessment • cGMP clinical trial materials production • Commercial-scale cGMP manufacturing • Non-GMP protein expression and purification • Cell line development • Upstream process development • Downstream purification development • Analytical and formulation development • Documentation and reporting to support regulatory filings Mission It is our mission to provide our global clients and partners with a complete range of premier contract development and manufacturing services for biologics and advanced therapies, from early custom development to clinical manufacturing, to further accelerate the development of high-quality biologics, meeting patients' needs and delivering long-lasting value to the biotech and biopharmaceutical industry.

Ab&B Biotech

Series C in 2021
Ab&B Biotech focuses on the research and development of innovative human vaccines and multivalent vaccines.

Dingdang Kuaiyao

Private Equity Round in 2021
Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.

Simcere Pharma

Series B in 2021
Founded on 28th March 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a research and development center and manages over 4,000 employees. They are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million.

Ark Biosciences

Series C in 2021
Ark Biosciences is a biopharmaceutical company that is dedicated to the discovery and development of innovative therapeutics to address unmet medical need, especially in the area of respiratory viral infection and viral hepatitis, for global and China market. We strive to build a science-driven biopharmaceutical company that aims to be a leader in antiviral drug discovery and development. To achieve so, we aspire for the excellence of science and be innovative. We operate with a razor-sharp focus and aggressiveness with a timely and cost efficient manner. We create a healthy and rewarding work environment for employees, and seek a superior rate of return for investors and partners.

Microread

Series C in 2020
Microread is a commercialization company that focuses on sequencing technology platforms for genetic detection. They refined production processes and quality verification, and they developed a series of economical test reagents for forensic, clinical, agricultural, animal husbandry, and research fields.

MicuRx Pharmaceuticals

Series E in 2020
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.

Denovo Biopharma

Series D in 2020
Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. The core technology is the industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology.

Qihe Biotech

Venture Round in 2020
Qihe Biotech engages in the research and development, production, processing, sales, and export of edible fungi. They provide technical guidance services for customers in different regions.

WM Motor

Series D in 2020
WM Motor is an automotive company that designs, manufactures, develops, and markets energy and battery-operated vehicles. It provides energy vehicle products and travel solutions to its customers. The company aims to conserve electronic vehicles in addition to intelligent data hardware, enabling consumers to utilize smart cars that are efficient and energy conserving. WM Motor’s products are built with three core technologies, the Living Motion electric powertrain, the Living Pilot intelligent driving assistance system, and the Living Engine operating system, which offers industry-leading smart connectivity and interactive features.

Adlai Nortye

Series C in 2020
Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates in development.

Hanyu Medical

Series D in 2020
Hanyu Medical is one of the first domestic companies to develop, produce, and sell transcatheter mitral valve repair devices. At present, the company’s core product is Valve Clamp, a mitral valve interventional device, which is used for minimally invasive interventional treatment of mitral valve regurgitation diseases.

Asieris Pharmaceuticals

Series C in 2020
Asieris Pharmaceuticals is a Chinese biotech company focusing on therapeutic areas in oncology and multidrug-resistant infections.

EOC Pharma Group

Series C in 2019
EOC Pharma is an integrated biopharmaceutical company that is focused on the manufacturing, development and commercialization of innovative global oncology products in China. They have adopted a licensing model in order to build EOC’s innovative pipeline by plugging their partner’s molecule into EOC’s “core engine” of local manufacturing, clinical development, regulatory filing, and commercialization. The company has a pipeline of seven novel products from global biopharmaceutical partners that are potentially first- and best-in-class. Until now, EOC has obtained four Class I innovative drug CTA approvals and initiated clinical studies of four lead products in China.,EOC has a team of entrepreneurs and consultants with overseas background that boasts of first-class pharmaceutical R&D expertise as well as rich industry experience. The company owns an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City and has offices in Shanghai, Beijing, Hong Kong and Los Angeles. EOC will leverage forward-looking licensing which will provide product opportunities to their integrated platform, generating a highly strategic portfolio. Ultimately, this will position EOC at the top of oncology innovation in China.

THOK LOGISTICS

Venture Round in 2019
THOK LOGISTICS provides solution services for supply chain logistics integrating consulting planning, system integration, logistics technology equipment product manufacturing, and software system research and development. It is a supply chain logistics solution provider.

Phylion Battery

Private Equity Round in 2019
Phylion Battery specializes in the development, production, and sales of lithium-ion batteries with lithium manganate as the positive electrode material. Its annual production capacity is 5GWh, which is a well-known high-tech enterprise of power lithium battery in China. Through 15 years of successful technology transformation, Phylion has provided products and services to 8 million end users and more than 45,000 electric vehicles worldwide, and provided power supply solutions for new energy vehicles around the world. Up to now, with 3GWh annual production capacity, Phylion has provided products and services for 8 million Light EV customers, 45 thousand EV customers, and various industrial projects all over the world.

Voc Acoustic Technology

Series A in 2019
Voc Acoustic Technology is a comprehensive acoustic technology enterprise integrating research, development, production and sales of acoustic products such as headphones, audio and smart wear. The company cut into the TWS true wireless headset field, providing acoustic research and production services to acoustic brands around the world.

Haihe Biopharma

Series B in 2019
HaiHe Biopharma is a developer of innovative anti tumor drugs designed to overcome complex diseases and improve pharmacological evaluation. The company focuses on discovery, development and commercialization of innovative anti-tumor drugs, pharmacological efficacy evaluation and provide products including novel topoisomerase I inhibitors and oral c-Met highly selective inhibitors, enabling customers to improve their health conditions and research quality in an efficient manner.

Heng Yi Biotechnology

Venture Round in 2019
Heng Yi provides services for nutritional and dietary supplements with high quality products at competitive prices. The company specializes in innovative formulations of nutritional supplements using natural ingredients and the highest quality raw material. Heng Yi's policy is to ensure the highest product quality at every stage of the manufacturing process,storage,distribution and sale.

Hanyu Medical

Series B in 2018
Hanyu Medical is one of the first domestic companies to develop, produce, and sell transcatheter mitral valve repair devices. At present, the company’s core product is Valve Clamp, a mitral valve interventional device, which is used for minimally invasive interventional treatment of mitral valve regurgitation diseases.

Chunmi Technology

Series C in 2018
Chunmi Technology manufactures rice cooker and kitchen appliances. Chunmi Technology was founded in 2013 and is headquartered in Shanghai, China.

Royole

Series E in 2018
Royole Corporation is a global pioneer and manufacturer of advanced flexible displays, flexible sensors, and smart devices. Royole Corporation's screens can be applied to smartphones, mobile devices, computers and televisions. The company is headquartered in Fremont, California, United States.

Health Engine

Corporate Round in 2018
Health Medical Technology is engaged in the intelligent management of medical equipment. They provide internet of things tools such as the self-developed equipment asset management platform and remote equipment management system, which realize the dynamics of intelligentization and dataization of the entire life cycle of medical equipment. They improve the efficiency of equipment operation, and realize the refined management of medical equipment through the mining and application of big data in medical equipment management.
Huizhou Yipeng Energy Technology Co., Ltd. is a developer, manufacturer, and marketer of the plug-in hybrid and pure electric vehicle.

Kanghua Biotechnology

Angel Round in 2018
Kanghua Biotechnology is a developer of diagnostic reagents.

LEADTHING

Post in 2018
LEADTHING is a software and information technology service company. They provide corresponding software products and solutions for customer information. Their products cover institutions, military, public security, and border defense.

JHOME

Post in 2018
JHOME is an import and export rights company and an Internet B2C sales platform for drugs and medical devices. Their production and sales of in vitro diagnostic reagents and instruments, medical imaging, and medical electronic equipment. They focus on product and technological innovation in the fields of medical care, family health, and public safety.

JAKI

Post in 2018
JAKI product research and development, and promotes development. They provides delivery services like .211 limited time, delivery service inquiry, shipping fee charging standard and overseas delivery. They also provides online education for the kids.

34learning

Seed Round in 2018
34learning provides products and services such as digital learning solutions, micro-consulting projects, mixed project courses, and traditional courses. They also offer online learning development solutions for their partners. Their courses include mixed learning, leadership development, professional development, personal ability development, and others.

Goldpro

Corporate Round in 2017
Goldpro is one professional manufacturer and exporter of grinding media steel balls in China. Besides supplying different sizes of grinding steel balls, the company also provides other services, like developing new special steel balls according to the ore conditions for its customers.

11ziyun.com

Post in 2017
11ziyun.com is a printing paper company. Their service platform spans e-commerce, logistics, cloud computing, big data, and cross border transaction services. They offer advertising materials, commercial printing, digital printing materials, design services, office supplies, student supplies, and paper pulps.

LC Securities

Series B in 2017
LC Securities is an integrated financial services platform in Guangdong. The company provides credit business, fixed income, and asset management services. The business focuses on offering Chinese high-net-worth individuals professional, effective, and convenient one-stop financing services.

Yondervision

Post in 2017
Yondervision is a supplier and service operator that provides digital solutions for housing provident funds. They also provide housing provident fund and financial services. Additionally, they also offer statistical reports and modeling tools for data analysis.

Sanyou Medical

Private Equity Round in 2017
Shanghai Sanyou Medical Co., Ltd is a corporation that is therapy innovation oriented and devotes to the R&D , manufacture and sales of independently innovative orthopedics implants . The headquarter is located in the Medical Apparatus Garden of Zhangjiang Hi-Tech Park , Shanghai . In September 2010 , a senior international management team finished the corporation restructuring and set up a brand new management mechanism to become a valuable and sustainable company .

Bright Key

Series A in 2017
Bright Key provides SAP services. They also provide consulting, implementation, operation, and maintenance services of SAP software products, including implementation services of various application modules of the SAP ERP system, enterprise SAP ERP system before receiving external audit consulting services, daily operation and maintenance, technical support, and tuning services of SAP ABAP and SAP Java programs, and more.

Zelgen

Series A in 2016
Zelgen is committed itself to the innovation, R&D, manufacture and sales of new medications. The goal of Zelgen is to become one of the leading biopharmaceutical companies in China for the treatments of cancer, hematologic diseases, etc. The business strategy of Zelgen is to focus on the domestic market and to fulfill the unmet medical needs through development of high quality, safe, efficacious and affordable new medications in China.

SMO ClinPlus

Venture Round in 2016
SMO ClinPlus provides SMO services to domestic and foreign pharmaceutical companies, medical device companies, and the clinical research and development of some health related products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.